NVIDIA CEO Jensen Huang continues to invest in generative AI, aiming to support medical research and accelerate the development climate solutions.
In March, the company launched BioNeMo Cloud, a set of generative AI cloud services to support researchers engaged in drug discovery. The services include DiffDock, the MIT-developed program developed under the direction of Regina Barzilay, AI faculty lead MIT Jameel Clinic, as well as AlphaFold2 by DeepMind, ESMFold and ESM2 by Meta, MoFlow by Cornell University and ProGTP-2. BioNeMe specifically supports protein folding research, which is necessary for new drug discovery, and a process made more efficient through AI assistance.
NVIDIA is also developing AI tools for climate adaptation in agriculture and for the development of new biofuels.